• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Meta-analytic evidence of increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII.

作者信息

Gruppo R A, Brown D, Wilkes M M, Navickis R J

出版信息

Haemophilia. 2004 Nov;10(6):747-50. doi: 10.1111/j.1365-2516.2004.01034.x.

DOI:10.1111/j.1365-2516.2004.01034.x
PMID:15569174
Abstract

A recent meta-analysis of 13 observational studies suggested reduced haemostatic efficacy during prophylaxis and shortened half-life of B-domain deleted factor VIII (BDD-rFVIII) as compared with full-length factor VIII (FL-FVIII). The meta-analysis included a multivariate model that took both dose and age into account. In addition, several assumptions and interpretations were required in order to conduct the meta-analysis. It is important to test the impact of such assumptions and interpretations through sensitivity analysis. In the published meta-analysis, results of several sensitivity analyses were described involving the effect of study design; heterogeneity of subjects in some studies; type of assay used for half-life determinations; and year of publication. In two subsequent brief reports, additional sensitivity analyses addressed choice of median-to-mean conversion factor over a wide range of scenarios and use of age at start of prophylaxis vs mean age during prophylaxis in the multivariate model. A recognized inherent difficulty in the meta-analysis of multiple published reports from similar studies is the possibility of some subject or data overlap. Therefore, the present communication details further sensitivity analyses encompassing assumptions regarding the possibility of subject duplication in a subgroup of subjects from one study and possible duplication of pharmacokinetic data from two smaller studies within the reports of two larger studies. All the sensitivity analyses support the main conclusions of the meta-analysis, namely, that BDD-rFVIII substantially increases the risk of breakthrough bleeding during prophylaxis, possibly at least partly because of shorter half-life than that of FL-FVIII.

摘要

相似文献

1
Meta-analytic evidence of increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII.
Haemophilia. 2004 Nov;10(6):747-50. doi: 10.1111/j.1365-2516.2004.01034.x.
2
Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.从全长 FVIII 治疗转换为 B 结构域缺失的 r-FVIII 并再转换回全长 FVIII 的患者的药代动力学、凝血因子消耗和临床疗效。
Haemophilia. 2009 Nov;15(6):1237-42. doi: 10.1111/j.1365-2516.2009.02071.x. Epub 2009 Aug 2.
3
Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.全长和B结构域缺失的凝血因子VIII用于预防的比较疗效——一项荟萃分析
Haemophilia. 2003 May;9(3):251-60. doi: 10.1046/j.1365-2516.2003.00769.x.
4
Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII--a robust meta-analytic finding.
Haemophilia. 2004 Sep;10(5):449-51. doi: 10.1111/j.1365-2516.2004.00931.x.
5
The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?FVIII 药代动力学与 TDM 和血友病 A 治疗的相关性:缺失 B 结构域的 FVIII 是否等同于全长 FVIII?
Ther Drug Monit. 2012 Feb;34(1):110-7. doi: 10.1097/FTD.0b013e318244fa5a.
6
Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - another rebuttal.全长及B结构域缺失的凝血因子VIII用于预防的比较效果——又一次反驳
Haemophilia. 2004 May;10(3):305-7. doi: 10.1111/j.1365-2516.2004.00898.x.
7
Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.回顾性分析血友病 A 患者每年第八因子利用情况的差异。
Haemophilia. 2012 Mar;18(2):187-92. doi: 10.1111/j.1365-2516.2011.02636.x. Epub 2011 Aug 24.
8
Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.重组B结构域缺失因子VIII(r-VIII SQ):A型血友病患者的药代动力学和初始安全性方面
Thromb Haemost. 1997 Feb;77(2):298-302.
9
Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X.B结构域在活化蛋白C和活化因子X对活化凝血因子VIII的蛋白水解失活中的作用。
Blood Coagul Fibrinolysis. 2006 Jul;17(5):379-88. doi: 10.1097/01.mbc.0000233368.95733.3c.
10
Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.加拿大针对重度甲型血友病幼儿的定制预防、初级预防和按需治疗的成本效用分析。
Haemophilia. 2008 Jul;14(4):743-52. doi: 10.1111/j.1365-2516.2008.01664.x. Epub 2008 Apr 16.

引用本文的文献

1
Blood Clotting Factor VIII: From Evolution to Therapy.凝血因子 VIII:从进化到治疗。
Acta Naturae. 2013 Apr;5(2):19-39.